EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serological Biomarkers in Individuals with Interstitial Lung Disease after SARS-CoV-2 Infection and Association with Post-COVID-19 Symptoms

Paula Parás-Bravo iD, César Fernández-de-Las-Peñas iD, Diego Ferrer-Pargada iD, Sheila Izquierdo-Cuervo, Luis M Fernández-Cacho, José M Cifrián-Martínez iD, Patricia Druet-Toquero, Oscar Pellicer-Valero iD, Manuel Herrero-Montes iD

Pathogens · 2024

DOI: 10.3390/pathogens13080641 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathogens, 2024. Verfasst von Paula Parás-Bravo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Enfermería, Universidad de Cantabria, 39005 Santander, Spain. Hauptthemen laut MEDLINE: COVID-19, Lung Diseases, Interstitial, Biomarkers, SARS-CoV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with interstitial lung disease (ILD) represent a vulnerable population against an acute SARS-CoV-2 infection. It has been observed that up to 80% of patients with ILD can develop post-COVID-19 symptomatology one year after. This secondary analysis aimed to, 1, compare serological biomarkers before and after surpassing a SARS-CoV-2 infection in individuals with interstitial lung disease (ILD) and, 2, to compare serological biomarkers between ILD patients who develop and those who do not develop post-COVID-19 symptoms. Seventy-six patients with ILD (40.4% women, age: 69, SD: 10.5 years) who survived a SARS-CoV-2 infection participated. High-resolution computerized tomography (CT) of the lungs, two pulmonary function tests (forced vital capacity (FVC) and diffusion value of carbon monoxide (DLCO)) and fourteen serological biomarkers were collected before and after SARS-CoV-2 infection. Participants were asked for the presence of post-COVID-19 symptomatology a mean of twelve (SD: eight) months after infection. Sixty patients (79%) showed post-COVID-19 symptoms (mean: 3.5, SD 1.1), with fatigue (68.4%), dyspnea (31.5%), and concentration loss (27.6%) being the most prevalent. Creatine phosphokinase (CPK) was the only biomarker showing differences in our study. In fact, CPK levels were higher after the acute SARS-CoV-2 infection (mean difference: 41.0, 95%CI 10.1 to 71.8, p = 0.03) when compared to before the infection. Thus, CPK levels were also higher in ILD patients with post-COVID-19 fatigue (mean difference: 69.7, 95%CI 12.7 to 126.7, p = 0.015) or with post-COVID-19 dyspnea (mean difference: 34.8, 95%CI 5.2 to 64.4, p = 0.025) than those patients without these post-COVID-19 symptoms. No significant changes in CT or functional pulmonary tests were observed after COVID-19 in patients with ILD. In conclusion, patients with ILD exhibited an increase in CPK levels after SARS-CoV-2 infection, albeit no changes in other serological biomarkers were identified. Similarly, the presence of post-COVID-19 fatigue or dyspnea was also associated with higher CPK levels in ILD patients. Studies investigating long COVID mechanisms in vulnerable populations such as ILD are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Lung Diseases, InterstitialBiomarkersSARS-CoV-2HumansFemaleMaleAgedMiddle AgedRespiratory Function TestsTomography, X-Ray ComputedPost-Acute COVID-19 SyndromeLungVital Capacity

Stichwörter der Autor:innen

SARS-CoV-2interstitial lung diseaselong COVIDpost-COVID-19serological biomarker

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Departamento de Enfermería, Universidad de Cantabria, 39005 Santander, Spain.
  • Grupo de Investigación en Enfermería, Instituto de Investigación Sanitaria Valdecilla (IDIVAL), 39011 Santander, Spain.
  • Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos (URJC), 28922 Madrid, Spain.
  • Servicio de Neumología, Hospital Universitario Marqués de Valdecilla, 39008 Cantabria, Spain.
  • Image Processing Laboratory (IPL), Universitat de València, Parc Científic, Paterna, 46980 Valencia, Spain.

ORCID-Profile: Paula Parás-Bravo, César Fernández-de-Las-Peñas, Diego Ferrer-Pargada, José M Cifrián-Martínez, Oscar Pellicer-Valero, Manuel Herrero-Montes

Zitieren

APA

Parás-Bravo, P., Fernández-de-Las-Peñas, C., Ferrer-Pargada, D., Izquierdo-Cuervo, S., Fernández-Cacho, L. M., Cifrián-Martínez, J. M., Druet-Toquero, P., Pellicer-Valero, O., & Herrero-Montes, M. (2024). Serological Biomarkers in Individuals with Interstitial Lung Disease after SARS-CoV-2 Infection and Association with Post-COVID-19 Symptoms. Pathogens. https://doi.org/10.3390/pathogens13080641

Vancouver

Parás-Bravo P, Fernández-de-Las-Peñas C, Ferrer-Pargada D, Izquierdo-Cuervo S, Fernández-Cacho LM, Cifrián-Martínez JM, et al. Serological Biomarkers in Individuals with Interstitial Lung Disease after SARS-CoV-2 Infection and Association with Post-COVID-19 Symptoms. Pathogens. 2024. doi:10.3390/pathogens13080641

BibTeX
@article{ParsBravo2024,
  author = {Parás-Bravo, Paula and Fernández-de-Las-Peñas, César and Ferrer-Pargada, Diego and Izquierdo-Cuervo, Sheila and Fernández-Cacho, Luis M and Cifrián-Martínez, José M and Druet-Toquero, Patricia and Pellicer-Valero, Oscar and Herrero-Montes, Manuel},
  title = {Serological Biomarkers in Individuals with Interstitial Lung Disease after SARS-CoV-2 Infection and Association with Post-COVID-19 Symptoms},
  journal = {Pathogens},
  year = {2024},
  doi = {10.3390/pathogens13080641}
}
Kostenlos starten →